Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Net Cash Flow (2018 - 2025)

UroGen Pharma's Net Cash Flow history spans 8 years, with the latest figure at $20.7 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 56.01% year-over-year to $20.7 million; the TTM value through Dec 2025 reached -$61.0 million, down 178.93%, while the annual FY2025 figure was -$61.0 million, 178.93% down from the prior year.
  • Net Cash Flow reached $20.7 million in Q4 2025 per URGN's latest filing, up from -$2.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $99.2 million in Q3 2023 to a low of -$94.8 million in Q3 2024.
  • Average Net Cash Flow over 5 years is $2.9 million, with a median of -$9.5 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: tumbled 551.35% in 2022, then skyrocketed 639.49% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$11.0 million in 2021, then soared by 343.45% to $26.7 million in 2022, then plummeted by 190.93% to -$24.3 million in 2023, then skyrocketed by 293.72% to $47.1 million in 2024, then crashed by 56.01% to $20.7 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Net Cash Flow are $20.7 million (Q4 2025), -$2.6 million (Q3 2025), and -$11.1 million (Q2 2025).